When to Initiate Highly Active Antiretroviral Therapy in Sub-Saharan Africa? A South African Cost-Effectiveness Study
- 1 January 2006
- journal article
- Published by SAGE Publications in Antiviral Therapy
- Vol. 11 (1), 63-72
- https://doi.org/10.1177/135965350601100103
Abstract
Large-scale programmes increasing access to highly active antiretroviral therapy (HAART) are being implemented in sub-Saharan Africa. However, cost-effectiveness of initiating treatment at different CD4 count thresholds has not been explored in resource-poor settings. A cost-effectiveness analysis was conducted from a public health perspective using primary treatment outcomes, healthcare utilisation and cost data (Jan 2004 local prices; US dollars 1=7.6 Rands) derived from the Cape Town AIDS Cohort. A Markov state-transition model was developed to estimate life-expectancy, lifetime costs, quality-adjusted life-years (QALYs), cost per life-year and QALY gained for initiating HAART at three CD4 cell count thresholds (350/microl), including the no antiretroviral therapy (No-ART) alternative. Each treatment option was compared with the next most effective undominated option. Mean life-expectancy was 6.2, 18.8, 21.0 and 23.3 years; discounted (8%) QALYs were 3.1, 6.2, 6.7 and 7.4; and discounted lifetime costs were US dollars 5,250, US dollars 5,434, US dollars 5,740, US dollars 6,588 for No-ART, and therapy initiation at 350/microl scenarios respectively. Clinical benefits increased significantly with early therapy initiation. Initiating therapy at 350/microl had an ICER of US dollars 1,137 versus therapy initiation at 200-350/microl. ICERs were sensitive to HAART cost. HAART is reasonably cost-effective for HIV-infected patients in South Africa, and most effective if initiated when CD4 count >200/microl. Deferring treatment to <200/microl would reduce the aggregate cost of treatment, but this should be balanced against the significant clinical benefits associated with early therapy.Keywords
This publication has 32 references indexed in Scilit:
- The Case for Earlier Treatment of HIV InfectionClinical Infectious Diseases, 2004
- A 42-Week Open-Label Study to Assess the Pharmacokinetics, Antiretroviral Activity, and Safety of Amprenavir or Amprenavir plus Ritonavir in Combination with Abacavir and Lamivudine for Treatment of HIV-Infected PatientsClinical Infectious Diseases, 2004
- Treatment for Adult HIV InfectionJAMA, 2004
- Improved Outcomes with Earlier Initiation of Highly Active Antiretroviral Therapy Among Human Immunodeficiency Virus–Infected Patients Who Achieve Durable Virologic Suppression: Longer Follow‐Up of an Observational Cohort StudyThe Journal of Infectious Diseases, 2003
- When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studiesAIDS, 2003
- Review of Human Immunodeficiency Virus Type 1–Related Opportunistic Infections in Sub‐Saharan AfricaClinical Infectious Diseases, 2003
- The Cost Effectiveness of Combination Antiretroviral Therapy for HIV DiseaseNew England Journal of Medicine, 2001
- Production gains from health care: what should be included in cost-effectiveness analyses?Social Science & Medicine, 1999
- Cost effectiveness of highly active antiretroviral therapy in HIV-infected patientsAIDS, 1999
- Profound immunosuppression across the spectrum of opportunistic disease among hospitalized HIV-infected adults in Abidjan, Côte dʼIvoireAIDS, 1997